BiomedVC

BiomedVC is a leading Swiss early-stage venture capital firm focused on investing in and building healthcare companies, particularly within the biotechnology and medical technology sectors. The firm actively seeks out intriguing scientific innovations and partners with founders to develop promising startups that aim to deliver improved medicines and medical solutions to patients. Their investment strategy emphasizes scientific excellence and the creation of both medical and commercial value.

Founded in 2021, BiomedVC operates as the investment vehicle for BioMedInvest IV, distinguishing itself from the earlier BioMedInvest I-III funds managed by BioMedPartners. The firm is headquartered in Basel, Switzerland, and targets early-stage European startups. They take an active role in the development of their portfolio companies, often serving as a lead investor or an active syndicate partner, leveraging their extensive network within academia, finance, and industry.

BiomedVC's investment focus is primarily on drug development, with a lesser degree of interest in diagnostics and medical technology. A notable recent investment includes leading a €9 million seed financing round for iDEL Therapeutics in March 2026, a German biotech company developing novel cancer therapies. They have also invested in T-Curx, a company in the biotechnology industry.

The team at BiomedVC comprises experienced investment professionals with diverse backgrounds in drug development, finance, science, and technology. Key members include Managing Partners Dr. Michael Wacker, Dr. Valentin Piëch, and Dr. Aristotelis Nastos, along with General Partners Dr. Markus Hosang and Thomas Möller, and CFO/Partner Stefan Fäs. This collective expertise allows the firm to provide comprehensive support and strategic guidance to its portfolio companies.